Welcome to our dedicated page for HeartSciences SEC filings (Ticker: HSCSW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
HeartSciences Inc. (HSCSW) files a range of reports and disclosures with the U.S. Securities and Exchange Commission that provide insight into its business as a healthcare information technology and medical technology company focused on AI-enhanced ECGs. These SEC filings cover its Nasdaq-listed common stock (HSCS) and warrants (HSCSW) and document regulatory, financial, and corporate events.
Through current reports on Form 8-K, HeartSciences discloses material developments such as amendments to its Equity Distribution Agreement for at-the-market offerings, progress and terms of its Regulation A unit offering, exchanges of debt into equity, and changes to its bylaws. Filings also reference press releases announcing financial results, business updates, and regulatory milestones, including FDA Breakthrough Device designation for an aortic stenosis ECG algorithm and the submission of the MyoVista wavECG device for 510(k) clearance.
Other 8-K filings describe Nasdaq listing matters, including a notice that the company had regained compliance with the minimum stockholders’ equity requirement for continued listing on The Nasdaq Capital Market. Governance-related filings detail amendments to the company’s equity incentive plan and grants of restricted stock units and stock options tied to regulatory and product milestones.
On Stock Titan’s filings page, users can review these documents alongside AI-powered summaries that explain the significance of each report. Investors can quickly locate quarterly and annual reports referenced in the 8-Ks, track capital-raising activities, and monitor warrant-related disclosures connected to the HSCSW symbol. Real-time updates from EDGAR and AI-generated highlights help readers understand how HeartSciences’ regulatory filings relate to its AI-ECG technology, MyoVista platforms, and Nasdaq-listed securities.
HeartSciences Inc. (HSCSW) – Form 144 filing
The notice covers a planned sale of 4,416 common shares through The Charles Schwab Corporation, expected on 29 Jul 2025 on NASDAQ. Based on the disclosed aggregate market value of $15,720.96, the implied price is roughly $3.56 per share. The stock was originally purchased on 08 Dec 2014 from the issuer. No other sales by the filer have occurred in the past three months, and the filer affirms no knowledge of undisclosed adverse information.
The issuer reports 1,934,280 shares outstanding, so the proposed sale equals about 0.23 % of outstanding stock. The form supplies no name or relationship of the seller, indicating only routine compliance with Rule 144 rather than a strategic shift. No financial performance data, guidance changes, or operational updates accompany the filing.